Hengrui Medicine (01276.HK) subsidiary obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for HRS-2129 tablets.

Wisdom Financial News APP, Hengrui Medicine (01276.HK) announced that its subsidiaries Shandong Shengdi Pharmaceutical Co., Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. have recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (referred to as the "NMPA") for HRS-2129 tablets, and will soon begin clinical trials.